Reimbursement

Medicare, Medicaid and most major insurance carriers provide coverage to evaluate a patient's ability to metabolize commonly prescribed cardiovascular drugs.

Genetic (molecular diagnostic and pharmacogenomic) tests are covered by Medicare, Medicaid and most major insurance carriers to evaluate a patient’s ability to metabolize commonly used cardiovascular drugs.

The FDA has issued a Black Box Warning on the Plavix label alerting patients that poor metabolizers are at greater risk for adverse cardiovascular events and informs them genetic testing can identify patients’ CYP2C19 metabolic function.